Table 1.

Demographic, clinical, and neuropathological data on human donors included in the immunohistochemical analyses

		CN	MCI	AD	F	P
IHC (n=53)		22 (11F, 11M)	10 (6F, 4M)	21 (11F, 10M)	-	-
Age at death (Years)		82.1 ± 10.9	88.7 ± 5.7	85.6 ± 8.5	1.89	0.16
Race (no.)		W(18); H(3); B(1)	W(8); H(1); B(1)	W(13); H(4); B(1); A (1); n.a. (2)	-	-
PMI (hours)		7.5 ± 4.0	8.3 ± 5.2	8.4 ± 4.9	0.18	0.84
MMSE score (n=15)		27.5 ± 2.9	23.5 ± 2.1	13.6 ± 8.8	8.86	0.0043
CDR score (n=29)		0.2 ± 0.4	1.5 ± 1.4	2.3 ± 1.0	8.019	0.0019
Brain neuropathology (severity score [n=38])	Braak stage	I-II (56%) III-IV (33%) V-VI (11%)	I-II (30%) III-IV (40%) V-VI (30%)	I-II (5%) III-IV (21%) V-VI (74%)	9.50	0.0005
	ABC (amyloid, Braak, CERAD)	1.93 ± 0.71	2.17 ± 0.58	2.74 ± 0.35	8.24	0.0013
	Aβ plaque	1.29 ± 1.20	2.00 ± 1.03	2.58 ± 0.98	4.71	0.0154
	NFTs	0.55 ± 0.55	1.78 ± 0.99	2.21 ± 0.96	10.70	0.0002
	NTs	0.49 ± 0.88	1.17 ± 0.75	1.92 ± 1.05	7.34	0.0022
	Atrophy	0.96 ± 1.02	1.11 ± 1.01	1.56 ± 0.94	1.42	0.2544

List of human donors (total N=53 subjects) included in histological analyses. IHC, immunohistochemistry; CN, cognitively normal; MCI, mild cognitive impairment; AD, Alzheimer’s disease; F, female, M, male; SD, standard deviation; W, White; B, Black; H, Hispanic; A, Asian; PMI, post-mortem interval; MMSE, Mini-Mental State Examination; CDR, Clinical dementia rating; n.a., not available. Paired brains with full neuropathological assessments were available for 38 human donors; Aβ, Amyloid-β protein; NFTs, neurofibrillary tangles; NTs, neuropil threads; Mean ABC scores were determined as follows: A, Aβ plaque score modified from Thal; B, NFT stage modified from Braak; C, Neuritic plaque score modified from CERAD. Group values are presented as mean ± standard deviation. F and P values were determined using one-way ANOVA with Tukey’s multiple comparisons test. P values presented in bold type demonstrate significance.